Oncolytics completes GOBLET enrollment and targets data readouts with final grant payment expected
+1 new source since this summary was written
Oncolytics Biotech announced that enrollment in its GOBLET Phase 1/2 study has been finished. The company said it will receive the last Pancreatic Cancer Action Network grant this quarter and plans to release Cohort 4 results in the fourth quarter of 2026, followed by initial Cohort 5 data in the first half of 2027. The trial, run at 17 German sites, evaluates pelareorep‑based regimens and has already shown median overall survival above expectations in Cohort 4.
Why it matters
The imminent grant payment adds cash to the balance sheet this quarter, as noted in the company press release. The scheduled data readouts provide a catalyst that could move the stock depending on the efficacy outcomes.
Key facts
- 1Enrollment in the GOBLET Phase 1/2 study was completed. investing.com
- 2Oncolytics expects to receive the final PanCAN grant payment in the current quarter. tradingview.com
- 3Cohort 4 results are slated for the fourth quarter of 2026. tradingview.com
- 4Initial Cohort 5 results are planned for the first half of 2027. tradingview.com
- 5The GOBLET study is being conducted at 17 centers in Germany. investing.com
- 6Pelareorep has received Fast Track designation from the U.S. FDA for colorectal, anal and pancreatic cancers. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.